Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy

Next Previous
Trial Profile

A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary) ; Entrectinib (Primary) ; Erlotinib (Primary) ; Ipatasertib (Primary) ; Olaparib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Vemurafenib (Primary) ; Vismodegib (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Ivosidenib; Paclitaxel; Pemigatinib
  • Indications Adenocarcinoma; Cancer; Carcinoma
  • Focus Therapeutic Use
  • Acronyms CUPISCO
  • Sponsors Roche

    • Most Recent Events

    • 24 Oct 2023 Primary endpoint (progression-free survival (PFS) in category 1 pts) has been met, according to Results presented at the 48th European Society for Medical Oncology Congress.
    • 24 Oct 2023 Primary analysis (n=436) of efficacy and safety were presented at the 48th European Society for Medical Oncology Congress.
    • 20 Oct 2023 Results presented in a Foundation Medicine media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top